ZCM
ACET icon

Ziegler Capital Management’s Adicet Bio ACET Stock Holding History

Ziegler Capital Management’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-2,422
Closed -$346K – 399
2022
Q4 		$346K Sell
2,422
-101
-4% -$25.2K 0.01% 364
2022
Q3 		$574K Buy
+2,523
New +$640K 0.03% 339

Other funds holding ACET

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Ziegler Capital Management's ACET Position: Q1 2023 in Review

Ziegler Capital Management sold out of Adicet Bio (ACET) in Q1 2023, closing a stake of 2,422 shares — an estimated $346K sold.

Ziegler Capital Management first reported a position in ACET in Q3 2022 and held it in 2 quarters. The position peaked at $574K in Q3 2022. 107 funds tracked by Wall St. Rank hold ACET as of Q1 2023.

  • Ziegler Capital Management reported no remaining Adicet Bio position as of Q1 2023 after selling out during the quarter.
  • Ziegler Capital Management sold 2,422 Adicet Bio shares in Q1 2023, an estimated $346K.
  • Ziegler Capital Management first reported a position in Adicet Bio in Q3 2022 and held it in 2 quarters.
  • Ziegler Capital Management's Adicet Bio position peaked at $574K in Q3 2022.
  • 107 funds tracked by Wall St. Rank held Adicet Bio as of Q1 2023.

Based on Ziegler Capital Management's 13F filing for Q1 2023, filed 4 May 2023.